If this trial provides evidence for an overadditive albuminuria-lowering effect through the combined use of finerenone and empagliflozin that is not counteracted by an excess risk of adverse events, then simultaneous initiation of an SGLT-2 inhibitor and finerenone could become the roadmap for maximal cardiorenal protection in patients with CKD and T2D in the future. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.